Über das salzsaure 3.3′‐Diamino‐4.4′‐dioxy‐arsenobenzol und seine nächsten Verwandten

Abstract

Die Yenge schwaukt etwns bei I'riipamteu verscbiedener Daistellung; auch die Alrt tier Aufliisung der festen Substanz, ob iii reinein Wnsser, in allioholhaltigem Wasber, in physiologischer Kochsalzlijsung, sowie die Schnelligkeit dcs Alkalizosatees spielen eine Ilolle. Minimale Abweichungen bewirkeu hier Verschiedenheiten: cs icheint , nls 01) k o 11 o i ti ul e Vorgftnge dabei im Spiclc sind.

The Composition of Ehrlich's Salvarsan: Resolution of a Century‐Old Debate

“…[a] R = 3-NH 2 -4-HOC 6 H 3 -; see Figure 1 have so far been unsuccessful, presumably because of the high reactivity and hydrogen bonding properties of the compound. The (RAs) n rings formed by salvarsan are of interest, especially the trimer, as an As 3 ring does not seem to have been confirmed before, although examples of both (RP) 3 and (RSb) 3 are known. [13] It is striking that the trimer and pentamer appear to be the main forms when R = 4-hydroxy-3-aminophenyl, whereas the hexamer and pentamer are the only characterized examples for R = phenyl.…”

“…[13] It is striking that the trimer and pentamer appear to be the main forms when R = 4-hydroxy-3-aminophenyl, whereas the hexamer and pentamer are the only characterized examples for R = phenyl. [1,7] (We note that West and co-workers found a peak corresponding to [(PhAs) 3 ] + in the EI mass spectrum of (PhAs) n , but concluded it to be a fragmentation ion rather than a true component of the mixture. [14] ) It has been accepted that salvarsan in the clinically administered form differs from the active form in vivo.…”

“…[1,2] Ehrlich synthesized the compound by the reaction of 3-nitro-4-hydroxyphenylarsonic acid with dithionite. [3] This simultaneously reduced the NO 2 group to NH 2 and As V to As I to give a material of formula 3-H 2 N-4-HOC 6 H 3 As (Scheme 1). The product was isolated as the hydrated hydrochloride salt of formula 3-H 2 N-4-HOC 6 H 3 As·HCl·H 2 O.…”

Organometallic Iridium Arene Compounds: The Effects ofC-Donor Ligands on Anticancer Activity

“…1 However, the use of metals in medicinal chemistry was neglected until the 1900s, when potassium dicyanoaurate (Figure 1, 1) was first reported for its use in tuberculosis, and a small number of compounds were reported for their leishmaniasis (disease caused by parasites of the Leishmania type) and antibacterial activities. In 1909, Paul Ehrlich first discovered the antisyphilitic activity of the drug arsphenamine (Salvarsan), an arsenic containing compound, (2). 2 This organoarsenic compound was the first modern chemotherapeutic agent, however, it was thought to contain an As=As double bond, until 2005, when after extensive mass spectrometric analysis, the structure was confirmed to have AsAs single bonds and exist as a mixture of cycloarsenic rings, with three and five arsenic centres.…”

“…In 1909, Paul Ehrlich first discovered the antisyphilitic activity of the drug arsphenamine (Salvarsan), an arsenic containing compound, (2). 2 This organoarsenic compound was the first modern chemotherapeutic agent, however, it was thought to contain an As=As double bond, until 2005, when after extensive mass spectrometric analysis, the structure was confirmed to have AsAs single bonds and exist as a mixture of cycloarsenic rings, with three and five arsenic centres. 3 It was not until 1952 when Dwyer reported the bacteriostatic and bactericidal activity of cobalt and ruthenium compounds, 4 that the field of bioinorganic chemistry began to rapidly expand.…”